TacticScaleWhat LeMaitre Vascular Does & How It Makes Money (LMAT)
Updated October 2026 · reflects LeMaitre Vascular's latest reported financials
Maker of medical devices and implants for vascular surgery. It earns revenue by selling vascular devices, biologic implants and grafts to hospitals and surgeons through its own direct sales force and through distributors, and it also charges for human tissue cryopreservation services.
How LeMaitre Vascular makes money
It earns revenue by selling vascular devices, biologic implants and grafts to hospitals and surgeons through its own direct sales force and through distributors, and it also charges for human tissue cryopreservation services.
What LeMaitre Vascular does
LeMaitre Vascular, Inc. develops, manufactures and markets devices and implants for vascular surgery, selling in the Americas, Europe, the Middle East, Africa and Asia Pacific. Its range covers catheters for clot removal, temporary blood-flow blockage and perfusion; carotid shunts; valvulotomes; titanium-clip vessel closure systems; radiopaque tape; and a phlebectomy system for varicose veins. A large part of the portfolio is biologic and graft products. These include the Artegraft bovine carotid artery graft for dialysis access, XenoSure, VascuCel and CardioCel patches, biosynthetic and LifeSpan ePTFE vascular grafts, and cryopreserved human allografts, along with tissue cryopreservation services. The company sells through a direct sales force and distributors. It was incorporated in 1983 as Vascutech, took the LeMaitre Vascular name in 2001, and is headquartered in Burlington, Massachusetts.
Products & services
- Artegraft biologic graft
- XenoSure biologic patch
- CardioCel and VascuCel patches
- LifeSpan ePTFE vascular grafts
- Embolectomy and occlusion catheters
- Cryopreserved allografts
What is LeMaitre Vascular worth?
On an owner-earnings DCF, LeMaitre Vascular's most-likely value is about $105 versus a recent price near $81 (30% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$35) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Shanghai MicroPort Endovascular MedTech (688016.SS) · Artivion (AORT) · Penumbra (PEN) · Edwards Lifesciences (EW) · Merit Medical Systems (MMSI)